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Abstract 
A novel approach was used to develop and validate a rapid, specific, accurate 
and precise reverse phase ultra performance liquid chromatographic (UPLC) 
method for the simultaneous determination of Sitagliptin phosphate mono-
hydrate and Metformin hydrochloride in pharmaceutical dosage forms. The 
chromatographic separation was achieved on Aquity UPLC BEH C8 100 x 
2.1 mm, 1.7 µm, column using a buffer consisting of 10 mM potassium dihydro-
gen phosphate and 2 mM hexane-1-sulfonic acid sodium salt (pH adjusted to 
5.50 with diluted phosphoric acid) and acetonitrile as organic solvent in a 
gradient program. The flow rate was 0.2 mL min
−1 and the detection wavelength 
was 210 nm. The limit of detection (LOD) for Sitagliptin phosphate monohydrate 
and Metformin hydrochloride was 0.2 and 0.06 µg mL
−1, respectively. The limit 
of quantification (LOQ) for Sitagliptin phosphate monohydrate and Metformin 
hydrochloride was 0.7 and 0.2 µg mL
−1, respectively. This method was validated 
with respect to linearity, accuracy, precision, specificity and robustness. The 
method was also found to be stability-indicating. 
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Introduction 
Sitagliptin phosphate monohydrate (SP) chemically, (3R)-3-amino-1-[3-(trifluoromethyl)-
5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one phos-
phate hydrate [1] is an oral anti-diabetic, which is available in 25 mg, 50 mg and 100 mg 
tablets for oral administration. SP is used  for the improvement of glycemic control in 
patients with type II diabetes mellitus as monotherapy or combination therapy with 
metformin or a peroxisome proliferatoractivated receptor gamma (PPAR) agonist (e.g., 
thiazolidinediones) when the single agent does not provide adequate glycemic control.  
Metformin hydrochloride (MH) chemically, 3-(diaminomethylidene)-1,1-dimethylguanidine 
hydrochloride [2] is an antidiabetic agent [3]. It is the drug of choice for the treatment of 
type II diabetes, particularly in overweight and obese people and individuals with normal 
kidney function. It works by lowering blood sugar and helping the body use insulin more 
efficiently. It is available in 500 mg, 850 mg and 1000 mg tablets (immediate release) and 
in 500 mg and 750 mg (slow release) for oral administration. Merck and Co. market SP in 
combination with MH in a single dosage form as Junumet™ [4]. In combination these are 
available in 50/500 mg and 50/1000 mg of SP and MH, respectively.  The chemical 
structures of MH, Metformin impurity-1, Metformin impurity-2, SP and Sitagliptin impurity 
are presented in Tab. 1. 
Ultra performance liquid chromatography (UPLC) is an innovative product that brought 
revolution in high performance liquid chromatography by outperforming conventional 
HPLC. UPLC provides the speed by using novel low micron particles that decreases 
chromatographic run times and also double peak capacity or resolution. The current 
method can be considered a green method because it uses eco-friendly, innovative UPLC 
technology that reduces the consumption of organic solvent, resulting in less waste. The 
reduction of the flow rate drastically reduces the mobile phase consumption, thus having 
obvious economic consequences. With significant improvements in resolution, sensitivity 
and speed can be achieved for chromatographic separations by minimizing the band 
spreading contributions of both the instrument and the column. UPLC system will eliminate 
significant time and cost per sample from analytical process while improving the quality of 
results,  and  the system allows chromatographers to work at higher efficiencies with a 
much wider range of linear velocities, flow rates and back pressures. UPLC photodiode 
array (PDA) detector detects and quantifies lower concentrations of sample analyte, trace 
impurities with maximum sensitivity and compares spectra across wavelengths and broad 
concentration ranges. It is easy to identify components that are difficult to detect by 
conventional HPLC-based methods.  
The literature reveals that some methods have been reported for metformin. Few UV 
spectrophotometric methods [5], HPLC [6–8] and ion-pair HPLC [9] method have been 
reported for the estimation of MH. SP is not yet official in any of the pharmacopoeia but 
MH is official in IP [10], BP [11] and USPNF [12]. Literature survey reveals that only 
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humans, rats and dogs  Additionally, some reviewed literature describes the 
spectroflourometric and spectrophotometric methods for the determination of SP in 
pharmaceutical dosage forms [16]. Also, in the reviewed literature UPLC HPLC method is 
not reported for the simultaneous estimation of the SP and MH in combined pharma-
ceutical dosage form. A method for determination of SP either alone or simultaneous with 
MH in the presence of SP degradation impurity by HPLC [17] is available, but the current 
method focuses not only on SP related impurities but also the impurities of MH. Because 
this method consumes less organic solvent, it can be considered a green method. 
Therefore, it was thought worthwhile to develop a simple, precise, accurate reverse phase 
ultra performance liquid chromatographic method for the simultaneous estimation of SP 
and MH in combined tablet dosage form. 
Tab. 1.   Name, chemical structure and chemical name of SP, MH and 3 impurities 
(Sitagliptin impurity, Metformin impurity-1 and Metformin impurity-2) 
No.  Name  Structure  IUPAC Name 
1  Sitagliptin 
phosphate 
F
F
F
N
N
N
N
CF3
O H N H2
OH
OH
O H
O
P
 
(3R)-3-Amino-1-[3-(trifluoro-
methyl)-5,6-dihydro[1,2,4]-
triazolo[4,3-a]pyrazin-7(8H)-yl]-
4-(2,4,5-trifluorophenyl)butan-
1-one phosphate 
2  Metformin 
hydrochloride  N
NH
N
NH2
NH2
Cl H
 
3-(Diaminomethylidene)-1,1-
dimethylguanidine hydrochloride 
3  Sitagliptin 
impurity 
F
F
F
N
N
N
N
CF3
O H N H
O
 
N-[(2R)-4-Oxo-4-[3-(trifluoro-
methyl)-5,6-dihydro[1,2,4]-
triazolo[4,3-a]pyrazin-7(8H)-yl]-
1-(2,4,5-trifluorophenyl)butan-
2-yl]acetamide 
4  Metformin 
impurity-1 
 
N
NH
N H
NH2
NH2
Cl H
 
1-(Diaminomethylidene)-3-
methylguanidine hydrochloride 
5  Metformin 
impurity-2 
N
N
N
NH2
N H2 NH2 
1,3,5-Triazine-2,4,6-triamine 
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Experimental 
Instrumentation and Chromatographic Conditions 
The UPLC system, used for method development, forced degradation studies and method 
validation was Waters Acquity UPLC™ system equipped with the binary solvent manager, 
sample manager,  column  heater  module and photodiode array detector (Waters 
Corporation, Milford, USA). Aquity UPLC BEH C8 (100 x 2.1 mm, 1.7 µm) was used as 
stationary phase. The mobile phase composition used was the buffer 10mM potassium 
dihydrogen phosphate and 2 mM hexane-1-sulfonic acid sodium salt (pH adjusted to 5.50 
with diluted phosphoric acid) and acetonitrile with gradient program [Time(min)/% 
acetonitrile): 0/8, 2/8, 4/45, 6/45, 8/8, 10/8]. Prior to use, the mobile phase was filtered by 
using 0.2 µm filter. The flow rate of the mobile phase was maintained at 0.2 mL min
−1 and 
water was used as sample diluent. The column temperature was 25°C and eluents were 
monitored at 210 nm. The injection volume for samples and standards was 0.5 µL. The 
total analysis run time was 10 min. 
Reagents 
Bulk sample of SP and MH were received from the research development department of 
Dr. Reddy’s laboratories limited, Hyderabad, India. Commercially available Janumet 
tablets were manufactured by Merck & Co., Inc., NJ, USA. Hexane-1- sulfonic acid sodium 
salt and acetonitrile (HPLC grade) were purchased from Merck specialties private limited, 
India. Water was deionized and purified on a Milli-Q
 water purification system (Millipore, 
Bedford, MA, USA) and used to prepare all solutions. 
Preparation of Solutions 
Standard Solutions 
A standard solution containing 50 µg mL
−1 of SP and 500 µg mL
−1 of MH was prepared by 
dissolving an appropriate amount of SP and MH in diluent. An impurity blend solution of 
Metformin impurity-1 & 2 and Sitagliptin impurity with 100 µg mL
−1  concentration was 
prepared in diluent. 
Sample Preparation 
To prepare the sample stock solution, tablets of Junumet™, each containing 50 mg of SP 
and 500 mg of MH, were accurately weighed and transferred into a clean and dry mortar, 
crushed to a fine powder. An appropriated amount was transferred into a 100mL 
volumetric flask, diluted to volume with diluent and sonicated for 10 min obtaining the final 
concentration  of  50 µg mL
−1  of SP and 500 µg mL
−1  of  the active pharmaceutical 
ingredient. The solution was filtered through 0.45 µm Millipore PVDF filter.
 
Validation procedure  
Method validation was performed as per ICH guidelines [18] for simultaneous 
determination of SP and MH in the formulations. The following validation characteristics 
were addressed: linearity, detection limit, quantification limit, precision, accuracy, 
robustness and specificity.  
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System Suitability Criteria 
The system suitability was assessed by five replicate analyses of the drugs at 
concentrations of 50 µg mL
−1 of SP and 500 µg mL
−1 of MH. The acceptance criteria was 
not more than 2.0% for the RSD for the peak areas and not more than 1.5 for tailing factor 
for the peaks of the both the drugs. 
Specificity – Forced Degradation Studies 
Forced degradation studies were performed on SP and MH to prove the stability- 
indicating property of the method. The stress conditions employed for degradation study of 
SP and MH include light exposure [19], heat (105°C), acid hydrolysis (0.1 N HCl), base 
hydrolysis (0.1 N NaOH), water hydrolysis and oxidation (3% H2O2). For light studies, the 
monitoring period was 10 days whereas for heat, acid, base and water hydrolysis it was 
48 h. Oxidation was carried out for 24 h. Peak purity of the principal peak in the chromato-
gram of stressed samples of SP and MH tablets was checked using PDA detector. 
Linearity of Response 
Linearity solutions were prepared from stock solution at five concentration levels from 
25 µg mL
−1 to 75 µg mL
−1 for SP and from 250 µg mL
−1 to 750 µg mL
−1 for MH. The slope, 
Y-intercept and correlation coefficient were calculated. 
Precision  
Repeatability (intra-day) 
The precision of the assay method was evaluated by carrying out six independent assays 
of SP and MH (50 µg mL
−1  of SP and 500 µg mL
−1  of MH) tablets against qualified 
reference standard. The percentage of RSD of six assay values was calculated.  
Intermediate Precision (inter-day) 
Different analysts from the same laboratory evaluated the intermediate precision of the 
method. This was performed by assaying the six samples of SP and MH tablets against 
qualified reference standard. The percentage of RSD of six assay values was calculated. 
Accuracy  
The accuracy of the method was evaluated in triplicate at three concentration levels, i.e. 
50%, 100% and 150% of target test concentration (50 µg mL
−1 of SP and 500 µg mL
−1 of 
MH) in tablets. The percentages of recoveries were calculated. 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The LOD and LOQ for SP and MH were estimated at a signal-to-noise ratio of 3:1 and 
10:1, respectively, by injecting a series of dilute solutions with known concentration.  
Robustness 
The robustness of an analytical procedure is a measure of its capability to remain 
unaltered by small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. To determine the robustness of the method, 
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impurity-2 was evaluated along with %RSD for five injections and tailing factors for SP and 
MH. The mobile phase flow rate was 0.20 mL min
−1; to study the effect of flow rate on 
resolution it was changed to 0.18 and 0.22 mL min
−1. The effect of column temperature on 
resolution was studied at 20°C and 30 °C (instead of 25°C).The effect of pH of the mobile 
phase on resolution was also studied at 5.3 and 5.7 (instead of 5.5). 
Solution stability and Mobile phase stability 
The stability of SP and MH in solution was determined by leaving test solutions of the 
sample and reference standard in tightly capped volumetric flasks at room temperature for 
48 h during which they were assayed at 12 h intervals. Stability of mobile phase was 
determined by analysis of freshly prepared sample solutions at 12 h intervals for 48 h and 
comparing the results with those obtained from freshly prepared reference standard 
solutions. The mobile phase was prepared at the beginning of the study period and not 
changed during the experiment. The % assay of the results was calculated for both the 
mobile phase and solution-stability experiments. 
Results and Discussion 
Method Development and optimization of stability-indicating assay method 
The main objective of the chromatographic method is to achieve the separation of 
metformin impurities (Impurity-1 & Impurity-2) from Metformin, Sitagliptin impurity from 
Sitagliptin and also major degradation products formed under varied  stress conditions. 
Sitagliptin (pKa = 7.7) and metformin (pKa = 12.4) are basic in nature. 
Two different C18 (Aquity BEH C18, 100 x 2.1 mm; 1.7 microns and Zorbax C-18, 50 x 4.6 
mm, 1.8 microns) Columns, one C8 Column (Aquity BEH C8, 100 x 2.1 mm; 1.7 microns) 
and Zorbax SB-CN, 50 x 4.6 mm, 1.8 microns columns were used for method 
development. For the initial trials Aquity BEH C18, 100 x 2.1 mm; 1.7 micron and Zorbax 
C-18, 50 x 4.6 mm, 1.8 microns columns were chosen with a mobile phase composition of 
phosphate buffer adjusted to pH 5.5 and Acetonitrile in various ratios in gradient mode. 
Good separation was observed between Metformin and Sitagliptin but no separation was 
observed between Metformin and its impurities and also the Metformin peak is early 
eluting. Further trials were carried out using Zorbax SB-CN, 100 x 4.6 mm, 1.8 microns 
and UPLC BEH C-8, 100 x 2.1 mm, 1.7 microns column using the same chromatographic 
conditions as above. In both cases,  Metformin impurities were not separated from 
Metformin; only the retention time of Metformin was increased slightly on Cyno column. 
Different trials were carried out at different pH (2–7) of the mobile phase but all the 
attempts were futile. Since Metformin is a highly polar compound further trials were carried 
out using ion pair reagent in the mobile phase. Finally, good separation (USP resolution 
>2) between Metformin and its impurities along with good retention of Metformin (retention 
time around 2.2min) was observed using UPLC BEH C-8, 100 x 2.1 mm, 1.7 microns 
column with mobile phase consisting of a buffer (10mM potassium dihydrogen phosphate 
and 2mM hexane-1-  sulfonic acid sodium salt, pH was adjusted to 5.50 with diluted 
phosphoric acid) and acetonitrile in a gradient program with a flow rate of 0.2 mL min
−1. In 
the above mentioned conditions all the impurities related to Metformin and Sitagliptin are 
well separated along with good peak shapes (USP Tailing < 1.5) of Metformin and 
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respectively.  The blend chromatogram of Sitagliptin and Metformin with impurities 
(Metformin impurity-1, Metformin impurity-2 and Sitagliptin impurity) is shown in Fig. 1. 
 
 
Fig. 1.   Typical chromatograms of (A) Impurities spiked chromatogram Tablet 
chromatogram (B) Tablet chromatogram. Chromatographic conditions: waters 
UPLC
TM BEH C8 (100 x 2.1 mm, 1.7 µm) column, mobile phase: buffer 10mM 
potassium dihydrogen phosphate and 2mm hexane-1-sulfonic acid (pH 5.5) and 
acetonitrile in gradient elution, flow: 0.2 mL min
−1, column temperature: 25°C, 
injection volume: 0.5µl and detection: 210 nm. 
Method Validation 
Validation of an analytical procedure is the process by which it is established, by 
laboratory  studies, that the performance characteristics of the procedure meet the 
requirements for the intended analytical applications. 
System Suitability 
The system suitability test solution was injected and the chromatographic parameters like 
relative standard deviation for replicate injections of SP and MH and the tailing factor for 
both SP and MH peaks are evaluated.  The relative standard deviation for replicate 
injections of both SP and MH was 0.30% and 0.40% for SP and MH, respectively. The 
tailing factor for both SP and MH peaks was 1.0 and 1.1 for SP and MH, respectively. This 
indicates the suitability of the system. 146  C. S. N. Malleswararao, M. V. Suryanarayana, and K. Mukkanti:   
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Fig. 2.   Degradation chromatograms (A) Thermal degradation (B) Photo degradation 
(C) Acid degradation chromatogram (D) Base degradation chromatogram (E) 
Oxidative degradation chromatogram (F) Water degradation chromatogram 
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Fig. 2.   (Cont.) 
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Specificity – Forced Degradation Studies 
Degradation was not observed in SP and MH stressed samples that were subjected to 
light and heat. However, the degradation was observed under base hydrolysis, acid 
hydrolysis, water and oxidative conditions. The peak purity test results derived from PDA 
confirmed that the SP and MH peaks were pure and homogeneous in all the analyzed 
stress conditions. This indicates that the method is specific and stability-indicating (Fig. 2). 
Purity angle for the selected drug components in all stress conditions was found to be less 
than the threshold angle. Data is recorded in Tab. 2. 
Tab. 2.   Degradation study data 
Degradation conditions  % SP  Peak purity  % MH  Peak purity 
Water reflux at 70°C for 48h  96.35  pass  95.50  pass 
0.1 N NaOH at 70°C for 48h  35.06  pass  78.37  pass 
0.1 N HCl at 70° for 48h  94.69  pass  94.01  pass 
3% H2O2 for 24 h  87.80  pass  91.95  pass 
Thermal (105°C for 10 days)  99.50  pass  99.58  pass 
UV (254 nm for 10 days)  99.82  pass  99.27  pass 
 
Linearity of Response 
Linear calibration plot for this method was obtained over the calibration ranges tested, i.e. 
from 25 µg mL
−1 to 75 µg mL
−1 for SP and from 250 µg mL
−1 to 750 µg mL
−1 for MH, and 
the correlation coefficient obtained was greater than 0.999 for both drugs. The results 
show that an excellent correlation existed between the peak area and concentration of the 
analyte. The results are listed in the Table 3. 
Tab. 3.   Linear regression equations and correlation coefficient 
Drug  Range (µg mL
−1)  Slope  Intercept  Correlation coefficient 
SP  250–750  3.975 x 103  −1.7863 x 103  0.9999 
MH  25–75  8.545 x 103  4.1987 x 104  0.9991 
 
Precision 
The precision of an analytical method gives information on the random error. It expresses 
agreement between a series of measurements obtained from multiple sampling of the 
same homogeneous sample under prescribed conditions. The percentage RSD values for 
the precision study was 0.60%, 0.60% (inter-day precision) and 0.50%, 0.72% (intra-day 
precision) for SP and MH, respectively. This confirms good precision of the method.  
Accuracy 
The percentage recovery of SP ranged from 99.75 to 101.27 and MH ranged from 98.32 to 
100.60. Very good recoveries were made at each added concentration. Data is presented 
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Tab. 4.   Recovery of the assay method  
Drug  Concentration (%)  % Mean recovery  % RSD 
SP    50    99.75  0.45 
SP  100  101.27  0.26 
SP  150  100.18  0.29 
MH    50  100.60  0.50 
MH  100  100.06  0.47 
MH  150    98.32  0.61 
 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The limit of detection of SP and MH was 0.2 and 0.06 µg mL
−1, respectively. The limit of 
quantification of SP and MH was 0.7 and 0.2 µg mL
−1, respectively.  
Robustness  
In all the deliberate varied chromatographic conditions (flow rate, column temperature and 
buffer pH), all analytes were adequately resolved and elution orders remained unchanged. 
The resolution between critical pairs, i.e. for MH and its impurity-2 was greater than 2.0 
and tailing factor for SP and MH was less than 1.2. Data is presented in Tab. 5. The assay 
variability of SP and MH was within ±1.1%. 
Tab. 5.   System suitability parameters and robustness 
Robustness parameter  Resolution 
between MH 
imp-2 and MH 
Tailing  
factor 
% RSD for  
5 replicates 
SP  MH  SP  MH 
Buffer pH 5.30  2.4  1.1  1.1  0.41  0.50 
Buffer pH 5.50  2.3  1.0  1.1  0.32  0.63 
Flow rate 0.18 mL/min  2.2  1.0  1.1  0.33  0.42 
Flow rate 0.22 mL/min  2.3  1.1  1.0  0.21  0.30 
Column temperature 20°C  2.1  1.1  1.0  0.20  0.31 
Column temperature 30°C  2.2  1.0  1.1  0.34  0.43 
 
Stability in Solution and in the Mobile Phase  
Relative standard deviation (%) for assay of SP and MH during solution stability and 
mobile phase stability experiments was within 1.2%. The results from solution stability and 
mobile phase stability experiments confirmed that standard solutions and solutions in the 
mobile phase were stable for up to 48 h during assay determination.  
Tablet Application  
Analysis was performed for commercially available innovator tablets. The mean assay (n = 
6) for SP and MH was 100.20% and 99.62%, respectively. The percentage RSD value for 
the six assay values was 0.54%, 0.63% for SP and MH, respectively. The results are 
presented in Table 6. 150  C. S. N. Malleswararao, M. V. Suryanarayana, and K. Mukkanti:   
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Tab. 6.   Analysis data of tablet 
Drug  Label claim 
(mg/tablet) 
Amount found* 
(mg/tablet) 
Assay 
(%) 
% RSD 
SP  50  50.1  100.20  0.54 
MH  500  499.5  99.62  0.63 
* Average of six estimations of tablet formulation. 
 
Conclusion 
A simple specific stability-indicating UPLC method has been  developed for the 
quantification of SP and MH simultaneously. This method has been validated and found to 
be specific, precise, accurate, linear, robust, rugged and linear for the detection and 
quantification of SP and MH. This method exhibited an excellent performance in terms of 
sensitivity and speed. The major advantage of this technique  is that  it is less time 
consuming and also eco-friendly because of its low consumption of organic solvents as 
compared to other analytical techniques. It helps in simultaneous estimation of SP and MH 
in pharmaceuticals i.e., in combination drugs. This method is suitable for routine analysis 
and quality control of pharmaceuticals.  
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